Background Microelimination of hepatitis C virus (HCV) among people living with human
immunodeficiency virus (HIV) may be feasible in Australia, given unrestricted access to …

Background Gay and bisexual men (GBM) are a key population affected by human
immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfection. We aimed to measure …

Abstract Background Modeling of the London hepatitis C virus (HCV) epidemic in men who
have sex with men (MSM) and are living with human immunodeficiency virus (HIV) …

To reach the WHO target of hepatitis C virus (HCV) elimination by 2025, Taiwan started to
implement free-of-charge direct-acting antiviral (DAA) treatment programme in 2017 …

Summary Background In the Netherlands, access to direct-acting antivirals (DAAs) against
hepatitis C virus (HCV) has been unrestricted for chronic infection since 2015. We evaluated …

Abstract Introduction The World Health Organization targets for hepatitis C virus (HCV)
elimination include a 90% reduction in new infections by 2030. Our objective is to review the …

Background High costs of direct-acting antivirals (DAAs) have led health-care insurers to
limit access worldwide. Using a natural experiment, we evaluated the impact of removing …

Abstract Background In 2016, the World Health Organization (WHO) introduced global
targets for the elimination of hepatitis C virus (HCV) by 2030. We conducted a nationwide …

Abstract The World Health Organization has set tremendous goals to eliminate viral hepatitis
by 2030. However, most countries are currently off the track for achieving these goals …

Background Direct acting antivirals (DAA s) have revolutionized hepatitis C (HCV) treatment
with> 90% cure rates even in real‐world studies, giving hope that HCV can be eliminated …